Neptune Wellness Solutions, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA64079L3039
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

10

Shareholding (Dec 2023)

FII

6.05%

Held by 74 FIIs

DII

93.65%

Held by 0 DIIs

Promoter

0.30%

How big is Neptune Wellness Solutions, Inc.?

22-Jun-2025

As of March 2023, Neptune Wellness Solutions, Inc. has an unavailable market capitalization, reported net sales of 39.12 million, a net loss of 78.82 million, negative shareholder funds of -11.94 million, and total assets of 30.93 million.

As of March 2023, Neptune Wellness Solutions, Inc. has a market capitalization value that is not available, which makes it difficult to classify its market cap type.<BR><BR>As of March 2023, the company reported net sales of 39.12 million for the latest four quarters. During the same period, the consolidated net profit was a loss of 78.82 million.<BR><BR>As of March 2023, the shareholder's funds were reported at -11.94 million, and the total assets amounted to 30.93 million.

Read More

Who are in the management team of Neptune Wellness Solutions, Inc.?

22-Jun-2025

As of March 2022, the management team of Neptune Wellness Solutions, Inc. includes Mr. John Moretz as Independent Chairman, Mr. Michael Cammarata as President and CEO, and several Independent Directors: Mr. Joseph Buaron, Mr. Michael De Geus, Dr. Ronald Denis, and Mr. Richard Schottenfeld.

As of March 2022, the management team of Neptune Wellness Solutions, Inc. includes Mr. John Moretz as the Independent Chairman of the Board, Mr. Michael Cammarata serving as the President, Chief Executive Officer, and Director, along with several Independent Directors: Mr. Joseph Buaron, Mr. Michael De Geus, Dr. Ronald Denis, and Mr. Richard Schottenfeld.

Read More

Is Neptune Wellness Solutions, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Neptune Wellness Solutions, Inc. is considered overvalued with deteriorating financial metrics, including a negative P/E ratio and EV to EBITDA, despite a recent stock surge, indicating a bleak long-term outlook.

As of 8 July 2024, the valuation grade for Neptune Wellness Solutions, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current financial metrics, particularly with a P/E ratio of -0.0027 and an EV to EBITDA ratio of -0.5617, both of which suggest a lack of profitability and negative enterprise value relative to earnings. Additionally, the ROE stands at an impressive 172.33%, but this is misleading due to the negative capital employed.<BR><BR>In comparison with peers, Cidara Therapeutics, Inc. has a P/E of -13.4584 and an EV to EBITDA of -7.9458, while MIRA Pharmaceuticals, Inc. shows an EV to EBITDA of -2.7591. These figures highlight that Neptune's valuation metrics are significantly worse than those of its peers. Despite a remarkable recent stock performance, with a 1-week return of 99.33% compared to the S&P 500's 1.05%, the long-term outlook remains bleak, as evidenced by a staggering 5-year return of -100%. Overall, Neptune Wellness Solutions, Inc. is currently overvalued.

Read More

Is Neptune Wellness Solutions, Inc. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Neptune Wellness Solutions, Inc. shows a neutral technical trend with mixed signals, having outperformed the S&P 500 recently but suffering significant long-term declines.

As of 19 August 2025, the technical trend for Neptune Wellness Solutions, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the moving averages indicate a mildly bearish stance on the daily chart. The KST shows a mildly bullish trend on both weekly and monthly periods, but the RSI and Bollinger Bands are signaling sideways movement. Additionally, the OBV is mildly bullish on the monthly timeframe. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 99.33% and 113.57%, respectively, compared to the S&P 500's 1.05% and 2.33%. However, longer-term returns over 3, 5, and 10 years are severely negative, indicating a substantial decline relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.80

stock-summary
Return on Equity

172.33%

stock-summary
Price to Book

-0.00

Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Dec 2023)
Net Profit:
-19 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-100.0%
0%
-100.0%
6 Months
0%
0%
0.0%
1 Year
-100.0%
0%
-100.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Neptune Wellness Solutions, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.56%
EBIT Growth (5y)
-206.10%
EBIT to Interest (avg)
-29.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.80
Sales to Capital Employed (avg)
1.33
Tax Ratio
0.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.54
EV to EBITDA
-0.56
EV to Capital Employed
-4.06
EV to Sales
0.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
172.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 74 Foreign Institutions (6.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -12.64% vs -17.92% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2023 is -262.26% vs 45.92% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.60",
          "val2": "8.70",
          "chgp": "-12.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.40",
          "val2": "-4.10",
          "chgp": "-324.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "3.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "1.70",
          "chgp": "-129.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.20",
          "val2": "-5.30",
          "chgp": "-262.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,328.80%",
          "val2": "-506.70%",
          "chgp": "-182.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is 7.79% vs 37.85% in Mar 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -5.21% vs 33.80% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.60",
          "val2": "48.80",
          "chgp": "7.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-46.70",
          "val2": "-63.90",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "1.50",
          "chgp": "53.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-41.90",
          "val2": "-11.60",
          "chgp": "-261.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.80",
          "val2": "-84.40",
          "chgp": "-5.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-938.60%",
          "val2": "-1,434.10%",
          "chgp": "49.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'23 - QoQstock-summary
Dec'23
Sep'23
Change(%)
Net Sales
7.60
8.70
-12.64%
Operating Profit (PBDIT) excl Other Income
-17.40
-4.10
-324.39%
Interest
1.60
3.20
-50.00%
Exceptional Items
-0.50
1.70
-129.41%
Consolidate Net Profit
-19.20
-5.30
-262.26%
Operating Profit Margin (Excl OI)
-2,328.80%
-506.70%
-182.21%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2023 is -12.64% vs -17.92% in Sep 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2023 is -262.26% vs 45.92% in Sep 2023

Annual Results Snapshot (Consolidated) - Mar'23stock-summary
Mar'23
Mar'22
Change(%)
Net Sales
52.60
48.80
7.79%
Operating Profit (PBDIT) excl Other Income
-46.70
-63.90
26.92%
Interest
2.30
1.50
53.33%
Exceptional Items
-41.90
-11.60
-261.21%
Consolidate Net Profit
-88.80
-84.40
-5.21%
Operating Profit Margin (Excl OI)
-938.60%
-1,434.10%
49.55%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2023 is 7.79% vs 37.85% in Mar 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -5.21% vs 33.80% in Mar 2022

stock-summaryCompany CV
About Neptune Wellness Solutions, Inc. stock-summary
stock-summary
Neptune Wellness Solutions, Inc.
Pharmaceuticals & Biotechnology
Neptune Wellness Solutions Inc. (Neptune) is a diversified and fully integrated health and wellness company. The Company is focused on building a portfolio of natural, plant-based consumer products. Neptune is a provider of turnkey product development and supply chain solutions to business customers across various health and wellness verticals, including legal cannabis and hemp, nutraceuticals and consumer packaged goods. The Company is engaged in cannabis and hemp operation with research, development and commercialization focused on the use of cannabinoids in household products. Its consumer brands include the Forest Remedies and Ocean Remedies brands. Under the Forest Remedies brand, Neptune offers a full line of health and wellness products with and without cannabidiol. The Ocean Remedies brand offers consumers a source of omega-3 supplements. Ocean Remedies krill oil offers high eicosapentaenoic acid, docosahexaenoic acid, phospholipid levels and astaxanthin, a natural antioxidant.
Company Coordinates stock-summary
Company Details
545 Prom du Centropolis Suite 100 , LAVAL QC : H7T 0A3
stock-summary
Tel: 1 450 68722621 617 9566736
stock-summary
Registrar Details